TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. logo
TCRR

TCR2 Therapeutics, Inc. (TCRR)

$1.30.78%

Live
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$1.3
Day's Range
$1.4
$1.23
52-Week Range
$5.54
1 month return17.31%
3 month return56.86%
1 year return74.76%
5 year return91.44%

Company Information

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2's proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
OrganizationTCR2 Therapeutics, Inc.
Employees105
CEODr. Garry E. Menzel M.B.A., Ph.D.
IndustryPharmaceuticals: Major

Analyst Recommendation

based on 10 analysts ratings

Buy
80%
Buy
20%
Hold
0%
Sell

Based on 10 Wall street analysts offering stock ratings for TCR2 Therapeutics, Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 797.69%

Current

$1.3

Target

$11.67

Recommendation Trend

Based on 10 analyst

Current1M Ago3M Ago
Buy
8
11
11
Hold
2
4
4
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
49.1M
Book Value
$5.14
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.8
Wall Street Target Price
11.67

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
0.25
Enterprise Value
-69049104
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
0.59

Technicals

Beta
1.76
50 Day MA
1.62
200 Day MA
2.48

Institutional Holdings

Mpm Asset Management, LLC

10.48%

TANG CAPITAL MANAGEMENT LLC

9.42%

MPM Oncology Impact Management LP

8.72%

Vanguard Group Inc

3.45%

Redmile Group, LLC

2.83%

K2 PRINCIPAL FUND LP

2.79%

Discover more

Frequently Asked Questions

What is TCR2 Therapeutics, Inc. share price today?

Can Indians buy TCR2 Therapeutics, Inc. shares?

How can I buy TCR2 Therapeutics, Inc. shares from India?

Can Fractional shares of TCR2 Therapeutics, Inc. be purchased?

What are the documents required to start investing in TCR2 Therapeutics, Inc. stocks?

What are today’s High and Low prices of TCR2 Therapeutics, Inc.?

What are today’s traded volumes of TCR2 Therapeutics, Inc.?

What is today’s market capitalisation of TCR2 Therapeutics, Inc.?

What is the 52 Week High and Low Range of TCR2 Therapeutics, Inc.?

How much percentage TCR2 Therapeutics, Inc. is down from its 52 Week High?

How much percentage TCR2 Therapeutics, Inc. is up from its 52 Week low?

What are the historical returns of TCR2 Therapeutics, Inc.?

Who is the Chief Executive Officer (CEO) of TCR2 Therapeutics, Inc.?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*